Generic Dasatinib - CML - Chronic myeloid leukemia
ARTICLES
FDA rejects Xspray's would-be rival to Bristol Myers' Sprycel on dosing, manufacturing concerns
July 11, 2023, Fierce Pharma
Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients With Chronic Myeloid Leukemia: A Multicenter Retrospective Study in Hubei Province, China
December 7, 2018, PubMed
Generics in China
May 2014, CML Advocates
FDA rejects Xspray's would-be rival to Bristol Myers' Sprycel on dosing, manufacturing concerns
July 11, 2023, Fierce Pharma
Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients With Chronic Myeloid Leukemia: A Multicenter Retrospective Study in Hubei Province, China
December 7, 2018, PubMed
Generics in China
May 2014, CML Advocates
